9 Meters Biopharma FY 2022: net loss $43.8M; diluted EPS −$3.38

Key figures from this report

These are the numbers 9 Meters Biopharma reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Net income−$43.8MAgainst −$36.8M in FY 202110-K income statement, on EDGAR
2. Diluted EPS−$3.38Against −$3.00 in FY 202110-K income statement, on EDGAR
3. Cash and cash equivalents$12.6M−73% from $47.0M in FY 202110-K balance sheet, on EDGAR
4. Cash from operations−$37.2MAgainst −$29.5M in FY 202110-K cash flow statement, on EDGAR